SP Formulations offers a unique, rapid, cost-effective formulation Screen of pH and Excipients for Early Development (SPEED), that can complement lead optimization efforts. This screen of buffers and excipients commonly used in formulation development adds to selection criteria by rank order of compounds by solubility. Data can be leveraged to design early formulation prototypes for ADME and other testing needs.
Formulation screening, via SP Formulations’ SPEED service, can inform selection criteria, formulation possibilities for a class of molecules, and preview difficulties that may be encountered in later formulation research. More thorough preformulation and formulation research can be executed for a select set of molecules, following nomination for full development.
SP Formulations, a Smithers Group Company, provides flexible contract research and development services to the pharmaceutical and biotechnology industries, delivering a broad range of services for small and large molecules in a variety of pharmaceutical dosage forms. SP Formulation’s facilities can meet a broad range of requirements, from small preclinical and clinical batches to commercial scale production, including analytical and manufacturing support. SP Formulations’ sister company, Synomics Pharma, co-located in Wareham, Mass., offers a full range of analytical and bioanalytical services, including GMP- and cGMP compliant testing. The leadership of Synomics Pharma also has contributed substantially to the Bioanalytical Quality Standards Initiative (BQSI), a pharmaceutical industry working group organized to develop documented quality management standards for bioanalysis in support of clinical trials.
SP Formulations offers conventional formulation development as well as novel approaches to drugs that are difficult to formulate.
This news was featured in Drug Discovery & Development magazine: Vol. 13, No. 3, April 2010, p. 36.